Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues
The Journal of Clinical Endocrinology & Metabolism · 18.11.2026 · 111 (12) · 3363-3366
DOI: 10.1210/clinem/dgag272 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.07.2026. Verfasst von Adrianna N Tilton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Foundation for Research and Education Excellence, PCOS Challenge, National Polycystic Ovary Syndrome Association.
Abstract (Originalsprache)
Background
Polycystic ovary syndrome (PCOS), renamed polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder affecting 4% to 20% of women worldwide. Prior analysis (2006-2015) demonstrated that PCOS/PMOS received disproportionately less US National Institutes of Health (NIH) funding compared with other chronic disorders of similar prevalence and/or morbidity, namely rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE). A number of bipartisan advocacy efforts have been made since.
Objective
To determine the impact of current advocacy efforts on NIH funding for PCOS/PMOS research.
Methods
NIH Research Portfolio Online Reporting Tools were queried.
Results
In 2016-22, mean annual NIH funding for PCOS/PMOS was $31.8 M vs $262.4 M (RA), $66.1 M (TB), and $420.4 M (SLE), a 48%, 577%, −15% and 689% difference, respectively, compared to 2006-2015. In 2016-2022 PCOS/PMOS research received 533 awards from 16 NIH Institute/Centers (ICs), with 44.8% of funding arising from the National Institute of Child Health and Human Development, compared with 68.4% in the prior study period. RA, TB, and SLE funding came from 27, 36, and 27 ICs, respectively.
Conclusion
In 2016-2022, PCOS/PMOS research funding by the NIH increased by ∼50% compared to 2006-2015, albeit still less than the increase and total funding for RA and SLE. There appeared to be greater interest in PCOS/PMOS by a higher number of ICs. Recent advocacy efforts appear to be associated with increasing NIH funding. However, much remains to be done to address persistent disparities in research funding for this highly prevalent and morbid women's health disorder.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dept. of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- PCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA, USA.
- Dept. of Healthcare Organization & Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
- Dept of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
ORCID-Profile: Ricardo Azziz
Förderung
- Foundation for Research and Education Excellence
- PCOS Challenge
- National Polycystic Ovary Syndrome Association
Zitieren
APA
Tilton, A. N., Ottey, S., Patterson, W., & Azziz, R. (2026). Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues. The Journal of Clinical Endocrinology & Metabolism, 111(12), 3363-3366. https://doi.org/10.1210/clinem/dgag272
Vancouver
Tilton AN, Ottey S, Patterson W, Azziz R. Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues. The Journal of Clinical Endocrinology & Metabolism. 2026;111(12):3363-3366. doi:10.1210/clinem/dgag272
BibTeX
@article{Tilton2026,
author = {Tilton, Adrianna N and Ottey, Sasha and Patterson, William and Azziz, Ricardo},
title = {Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {12},
pages = {3363--3366},
doi = {10.1210/clinem/dgag272}
}
EUVIMED